Holen Sie sich die Stockscreener-App
8.48
5.60%
0.45
Handel nachbörslich:
8.66
0.18
+2.12%
Schlusskurs vom Vortag:
$8.03
Offen:
$8.08
24-Stunden-Volumen:
2.44M
Relative Volume:
1.22
Marktkapitalisierung:
$1.47B
Einnahmen:
$25.55M
Nettoeinkommen (Verlust:
$-341.97M
KGV:
-3.0286
EPS:
-2.8
Netto-Cashflow:
$-304.44M
1W Leistung:
+11.14%
1M Leistung:
+34.82%
6M Leistung:
+163.35%
1J Leistung:
+80.04%
1-Tages-Spanne:
$8.005
$8.53
1-Wochen-Bereich:
$7.42
$8.70
52-Wochen-Spanne:
$1.775
$8.70
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
60 HAMPSHIRE STREET, CAMBRIDGE
Vergleichen Sie RLAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
8.48 | 1.39B | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-04-17 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Relay Therapeutics (NASDAQ:RLAY) Trading Up 4.7%Here's What Happened - MarketBeat
Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 - Yahoo Finance
Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? - Yahoo Finance
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares - AOL.com
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year HighStill a Buy? - MarketBeat
Bellevue Group AG Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Wells Fargo Upgrades Relay Therapeutics (RLAY) - Nasdaq
Why Is Relay Therapeutics Stock Gaining Friday?Relay Therapeutics (NASDAQ:RLAY) - Benzinga
RLAY Stock Receives Analyst Upgrade and Price Target Boost | RLA - GuruFocus
Relay Therapeutics stock hits 52-week high at 8.62 USD By Investing.com - Investing.com Nigeria
Relay Therapeutics stock hits 52-week high at 8.62 USD - Investing.com
Relay Therapeutics Reports 'Robust Activity' in Study of Zovegalisib to Treat Breast Cancer - marketscreener.com
Relay Therapeutics (RLAY) Shares New Data from Zovegalisib Study - GuruFocus
Relay Therapeutics unveils efficacy subset analysis for zovegalisib at SABCS25 - Traders Union
Relay Therapeutics Announces Efficacy Subset Analysis of - GlobeNewswire
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
149,701 Shares in Relay Therapeutics, Inc. $RLAY Acquired by HighVista Strategies LLC - MarketBeat
Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy - MSN
Norges Bank Buys Shares of 835,874 Relay Therapeutics, Inc. $RLAY - MarketBeat
Diadema Partners LP Has $151,000 Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Mixed Investor Sentiment Surrounds Relay Therapeutics Stock - AD HOC NEWS
Growth Value: Why Relay Therapeutics Inc stock could outperform in 20252025 Market Trends & Technical Pattern Recognition Alerts - moha.gov.vn
JPMorgan Chase & Co. Reduces Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Down 5%What's Next? - MarketBeat
Relay Therapeutics, Inc. $RLAY Position Lifted by Franklin Resources Inc. - MarketBeat
Is Relay Therapeutics Inc. stock gaining market shareJuly 2025 Rallies & Low Drawdown Investment Strategies - Newser
Relay Therapeutics, Inc. $RLAY Shares Bought by Geode Capital Management LLC - MarketBeat
XTX Topco Ltd Raises Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Is Relay Therapeutics Inc. stock a buy on dipsWeekly Trade Analysis & Fast Moving Stock Trade Plans - Newser
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
What makes Relay Therapeutics Inc. stock attractive to growth fundsMarket Performance Recap & Expert Curated Trade Ideas - moha.gov.vn
RLAY Stock Price and Chart — NASDAQ:RLAY - TradingView
Barclays Sticks to Its Buy Rating for Relay Therapeutics (RLAY) - The Globe and Mail
Relay Therapeutics stock hits 52-week high at $7.65 By Investing.com - Investing.com Nigeria
Relay Therapeutics stock hits 52-week high at $7.65 - Investing.com
Should I hold or sell Relay Therapeutics Inc. stock in 2025CEO Change & AI Based Buy and Sell Signals - newser.com
Key metrics from Relay Therapeutics Inc.’s quarterly data2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
Is Relay Therapeutics Inc. stock a top momentum playJuly 2025 Drop Watch & Daily Market Momentum Tracking - newser.com
Relay Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Price Swings & Capital Protection Trading Alerts - newser.com
Relay Therapeutics Inc. (RLAY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com
Commit To Buy Relay Therapeutics At $5, Earn 22.4% Annualized Using Options - Nasdaq
Citizens reiterates Market Outperform rating on Relay Therapeutics stock By Investing.com - Investing.com Canada
Persistent Asset Partners Ltd Decreases Stock Position in Relay Therapeutics, Inc. $RLAY - MarketBeat
What analysts say about Relay Therapeutics Inc stockChart Pattern Recognition & Outstanding Growth Strategies - earlytimes.in
How Relay Therapeutics Inc. stock compares to growth peersTrade Performance Summary & AI Optimized Trade Strategies - newser.com
Is Relay Therapeutics Inc. stock positioned for long term growth - newser.com
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):